| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24018 |
| Drug |
Relugolix with estradiol and norethisterone acetate |
| Brand |
Ryeqo® |
| Indication |
Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. |
| Rapid review commissioned |
28/05/2024 |
| Rapid review completed |
15/07/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of relugolix combination therapy compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/07/2024 |
| Pre-submission consultation with Applicant |
18/02/2025 |
| Full submission received from Applicant |
15/07/2025 |
